Redeye endorses aXichem’s new order of USD280,000 from Iovate.
The guaranteed right issue will secure growth capital supporting the US launch and to advance the Eu...
Inga tecken på vikande konjunktur utanför konsument Med 12% organisk tillväxt accelererade Elanders ...
Efter att Starboard köpt en majoritetspost… I slutet av september köpte det brasilianska investmentb...
Impressive earnings despite a difficult market Adj.
’22e-‘24e EBIT estimates down 1-13% Orderbook growth likely to contract in tougher times Net cash ...
Q3 report due on Wednesday, 9 November We expect results to largely mirror Q2 Worrisome if additio...
Aspo upgraded its FY ‘22 guidance, thanks to ESL’s continued strong performance, and gave an update ...
With a ~70% payout yield up to 2024E, capital repatriation remains key for the BankNordik share.
Elanders presented a strong Q3 report, with group organic growth of 12% y/y and 81% adjusted EBIT gr...
Q3 report due Friday, 28 October ’22e-’24e EBIT down on inventory challenges EFUEL earn-out likely r...
Redeye states its view on today’s September ARR update from Hoylu that closing its third quarter.
Redeye views Artificial Solutions’ Q3 2022 results in a positive light.
Subgruppsresultaten från Chordates kliniska studie PM007 presenterades i samband med Migraine Trust ...
We have taken a sceptical view regarding the potential threat from Sparsentan (Travere Therapeutics)...
Aspo sold its Telko Segment’s Russian operations for EUR 9.
Redeye comments on Carasent’s Q3 preliminary numbers.
Redeye comments on Tessin’s Q3 results, which came in higher than expected in terms of sales and low...
Vaisala upgraded its 2022 guidance and published preliminary figures for Q3’22.
Redeye comments on the preliminary results from CAPAFOUR and CESTAFOUR and the decision not to conti...
